PriceTargets.com logo

NASDAQ:KPTI - Karyopharm Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.67
  • Forecasted Upside: 238.44 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.22 As of 10/25/2021 05:00 PM ET
▼ -0.05 (-0.95%)

This chart shows the closing price for KPTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Karyopharm Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KPTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KPTI

Analyst Price Target is $17.67
▲ +238.44% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $17.67, with a high forecast of $27.00 and a low forecast of $6.00. The average price target represents a 238.44% upside from the last price of $5.22.

This chart shows the closing price for KPTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Karyopharm Therapeutics. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021Morgan StanleyLower Price TargetOverweight$29.00 ➝ $27.00Medium
8/13/2021Morgan StanleyReiterated RatingBuy$29.00Low
8/6/2021Robert W. BairdLower Price TargetAverage ➝ Outperform$30.00 ➝ $17.00High
8/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$6.00High
8/6/2021HC WainwrightLower Price TargetBuy$49.00 ➝ $26.00High
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
8/5/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$17.00 ➝ $8.00High
5/27/2021Robert W. BairdReiterated RatingBuyLow
5/4/2021Robert W. BairdLower Price TargetOutperform$35.00 ➝ $30.00High
5/4/2021Royal Bank of CanadaLower Price TargetOutperform$24.00 ➝ $19.00High
5/3/2021SVB LeerinkLower Price TargetOutperform$22.00 ➝ $15.00High
4/11/2021Royal Bank of CanadaReiterated RatingBuy$24.00Medium
2/12/2021BarclaysLower Price TargetOverweight$26.00 ➝ $22.00Low
2/11/2021SVB LeerinkLower Price TargetOutperform$25.00 ➝ $22.00Low
2/1/2021BarclaysLower Price TargetPositive ➝ Overweight$31.00 ➝ $26.00Low
1/12/2021SVB LeerinkLower Price TargetOutperform$29.00 ➝ $25.00High
11/3/2020Morgan StanleyLower Price TargetOverweight$34.00 ➝ $32.00High
11/3/2020SVB LeerinkLower Price TargetOutperform$30.00 ➝ $28.00High
8/4/2020SVB LeerinkLower Price TargetOutperform$31.00 ➝ $30.00Medium
7/14/2020Robert W. BairdSet Price TargetBuy ➝ Outperform$25.00 ➝ $35.00Medium
7/14/2020HC WainwrightReiterated RatingBuy$41.00Medium
7/1/2020Morgan StanleyInitiated CoverageOverweight$34.00Medium
6/23/2020JPMorgan Chase & Co.Boost Price TargetOverweight$31.00 ➝ $37.00High
6/23/2020Royal Bank of CanadaBoost Price TargetOutperform$28.00 ➝ $30.00High
6/23/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $41.00Medium
6/23/2020WedbushBoost Price TargetNeutral$18.99 ➝ $26.00Medium
6/23/2020BarclaysReiterated RatingBuy$31.00High
6/8/2020Royal Bank of CanadaReiterated RatingBuy$28.00High
5/24/2020HC WainwrightReiterated RatingBuy$40.00High
5/14/2020HC WainwrightReiterated RatingBuyMedium
5/6/2020Canaccord GenuityReiterated RatingBuyMedium
5/6/2020HC WainwrightLower Price TargetBuy$43.00 ➝ $40.00High
5/5/2020SVB LeerinkLower Price TargetOutperform$30.00 ➝ $29.00High
4/13/2020Royal Bank of CanadaReiterated RatingBuy$34.00High
4/7/2020WedbushReiterated RatingHold$25.00High
3/4/2020BarclaysInitiated CoverageOverweight$30.00High
3/3/2020Canaccord GenuityReiterated RatingPositive ➝ Buy$22.00 ➝ $35.00High
3/2/2020WedbushBoost Price TargetNeutral ➝ Positive$19.00 ➝ $25.00High
3/2/2020HC WainwrightBoost Price TargetPositive ➝ Buy$40.00 ➝ $43.00High
3/2/2020SVB LeerinkBoost Price TargetOutperform ➝ In-Line$22.00 ➝ $30.00High
1/17/2020WedbushDowngradeOutperform ➝ NeutralHigh
1/14/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $37.00Medium
1/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$23.00 ➝ $27.00High
1/3/2020Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
12/23/2019HC WainwrightReiterated RatingBuy$36.00N/A
12/12/2019Canaccord GenuityReiterated RatingBuy$22.00Low
11/6/2019WedbushBoost Price Target$15.00 ➝ $18.00Low
11/5/2019HC WainwrightBoost Price TargetBuy$32.00 ➝ $36.00High
9/24/2019Robert W. BairdSet Price TargetBuy$25.00Low
9/17/2019WedbushBoost Price TargetOutperform$11.00 ➝ $15.00Low
7/23/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$8.00 ➝ $16.00High
7/8/2019WedbushBoost Price Target$6.00 ➝ $11.00Low
7/5/2019Robert W. BairdReiterated RatingOutperform ➝ Outperform$15.00 ➝ $25.00High
7/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $32.00High
3/1/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$21.00 ➝ $7.00Low
2/27/2019HC WainwrightReiterated RatingBuyHigh
2/27/2019Bank of AmericaDowngradeNeutral ➝ Underperform$15.00 ➝ $5.00High
2/25/2019WedbushLower Price TargetOutperform ➝ Outperform$19.00 ➝ $14.00Medium
1/3/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
12/3/2018HC WainwrightReiterated RatingBuyHigh
11/30/2018B. RileyInitiated CoverageBuy ➝ Buy$23.00Low
11/9/2018WedbushUpgradeNeutral ➝ Outperform$19.00Low
11/7/2018HC WainwrightReiterated RatingBuy$30.00Medium
8/29/2018HC WainwrightReiterated RatingBuy$30.00High
8/8/2018Robert W. BairdReiterated RatingBuy$25.00Medium
8/7/2018Canaccord GenuityReiterated RatingBuy$27.00Medium
6/15/2018HC WainwrightReiterated RatingBuyLow
5/24/2018WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $19.00High
5/17/2018HC WainwrightReiterated RatingBuy$30.00Low
5/1/2018SVB LeerinkReiterated RatingOutperform$19.00 ➝ $24.00High
4/30/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
4/25/2018Jefferies Financial GroupReiterated RatingBuyMedium
4/24/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
4/10/2018Canaccord GenuityReiterated RatingBuy$22.00Low
4/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$19.00 ➝ $20.00High
4/2/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$19.00High
3/21/2018Cantor FitzgeraldSet Price TargetBuy$18.00Low
3/16/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$18.00 ➝ $19.00Low
3/15/2018Robert W. BairdSet Price TargetBuy$22.00Medium
3/15/2018HC WainwrightBoost Price TargetBuy$26.00High
3/15/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
3/12/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$18.00 ➝ $22.00Medium
3/2/2018Royal Bank of CanadaReiterated RatingBuy$22.00High
1/25/2018Cantor FitzgeraldReiterated RatingBuy$18.00High
12/12/2017Cantor FitzgeraldSet Price TargetBuy$18.00High
12/12/2017HC WainwrightReiterated RatingBuy$23.00High
11/15/2017HC WainwrightReiterated RatingBuy ➝ Buy$23.00N/A
11/3/2017Royal Bank of CanadaReiterated RatingBuy$15.00N/A
11/3/2017Robert W. BairdReiterated RatingBuyN/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$14.00N/A
10/13/2017Jefferies Financial GroupReiterated RatingBuyN/A
10/12/2017Cantor FitzgeraldSet Price TargetBuy$18.00N/A
9/20/2017Cantor FitzgeraldReiterated RatingBuy$18.00High
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform$14.00High
8/10/2017Jefferies Financial GroupReiterated RatingBuy$16.00 ➝ $19.00Medium
8/8/2017Canaccord GenuitySet Price TargetBuy$18.00High
7/14/2017Jefferies Financial GroupReiterated RatingBuy$16.00Low
7/4/2017Robert W. BairdReiterated RatingOutperform$15.00High
6/24/2017Cantor FitzgeraldSet Price TargetBuy$18.00High
5/15/2017Cantor FitzgeraldReiterated RatingOverweight$18.00Low
4/7/2017Jefferies Financial GroupReiterated RatingBuy$17.00High
4/6/2017Robert W. BairdReiterated RatingOutperform$15.00Low
4/5/2017WedbushReiterated RatingOutperform$14.00Medium
3/17/2017HC WainwrightReiterated RatingBuy$14.00Medium
3/13/2017WedbushReiterated RatingOutperform$14.00Low
3/13/2017Canaccord GenuityReiterated RatingBuy$20.00Low
3/13/2017Jefferies Financial GroupReiterated RatingBuy$14.00High
3/7/2017HC WainwrightReiterated RatingBuy$15.00 ➝ $14.00N/A
3/4/2017WedbushReiterated RatingOutperform$14.00N/A
3/3/2017Jefferies Financial GroupReiterated RatingBuy$14.00N/A
12/7/2016WedbushReiterated RatingOutperform$14.00N/A
12/4/2016Jefferies Financial GroupReiterated RatingBuy$12.00 ➝ $14.00N/A
11/8/2016Canaccord GenuityReiterated RatingBuyN/A
11/8/2016HC WainwrightReiterated RatingBuyN/A
11/8/2016WedbushReiterated RatingOutperform$14.00N/A
11/8/2016Jefferies Financial GroupReiterated RatingBuy$12.00N/A
(Data available from 10/26/2016 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
8/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2021

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Karyopharm Therapeutics logo
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational
Read More

Today's Range

Now: $5.22
Low: $5.19
High: $5.34

50 Day Range

MA: $5.61
Low: $4.45
High: $6.52

52 Week Range

Now: $5.22
Low: $4.42
High: $18.00

Volume

629,705 shs

Average Volume

1,105,782 shs

Market Capitalization

$394.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Karyopharm Therapeutics?

The following sell-side analysts have issued research reports on Karyopharm Therapeutics in the last twelve months: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for KPTI.

What is the current price target for Karyopharm Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Karyopharm Therapeutics in the last year. Their average twelve-month price target is $17.67, suggesting a possible upside of 238.4%. Morgan Stanley has the highest price target set, predicting KPTI will reach $27.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $6.00 for Karyopharm Therapeutics in the next year.
View the latest price targets for KPTI.

What is the current consensus analyst rating for Karyopharm Therapeutics?

Karyopharm Therapeutics currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KPTI, but not buy more shares or sell existing shares.
View the latest ratings for KPTI.

How do I contact Karyopharm Therapeutics' investor relations team?

Karyopharm Therapeutics' physical mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company's listed phone number is (617) 658-0600 and its investor relations email address is [email protected] The official website for Karyopharm Therapeutics is www.karyopharm.com.